Faeth Therapeutics, Inc. (FTH) Stock Analysis & Investment Frameworks
Faeth Therapeutics, Inc. (FTH) stock analysis on Invetso. Review Faeth Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Faeth Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Faeth Therapeutics, Inc. Key Financial Metrics
- Market Cap: $568.42M
- Revenue: $N/A
- ROE: -153.55%
- ROIC: -128.56%
- Dividend Yield: N/A
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]